Grupo para la caracterización molecular de las neoplasias hematológicas
Columbia University Medical Center
Nueva York, Estados UnidosPublications in collaboration with researchers from Columbia University Medical Center (2)
2022
-
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab
Blood, Vol. 140, Núm. 8, pp. 839-850